Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (2754)	6/5/2012 9:43:52 AM
From: scaram(o)uche	Respond to of 3202

Good question.... old paper, but these guys ought to know your answer by now (and were obviously leaning to "independent"). Pseudo Biologist probably knows the answer...... ncbi.nlm.nih.gov CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms (snip) For example, it has been shown that CTLA-4-B7 interactions lead to the induction of indoleamine 2,3-dioxygenase in tolergenic dendritic cell (DC) populations (42, 44). Thus, loss of CTLA-4 would lead to a T-cell defect but would also result in the loss of tolergenic DCs, leading to a more severe form of immune dysregulation. The implication of the DNA microarray data is that PD-1 engagement interferes with more pathways required for T-cell activation than does CTLA-4 engagement.

To: Biomaven who wrote (2754)	6/5/2012 10:07:52 AM
From: scaram(o)uche	Respond to of 3202

Aside.... by merely participating in this discussion and after the new bmy data, I acknowledge the possibility of "foot in mouth" lasting ~ 25 years. Hoping that Jim Allison will be seriously considered for Nobel.

To: Biomaven who wrote (2754)	7/24/2013 8:51:49 PM
From: scaram(o)uche	Respond to of 3202

Cited by Creelan et al., this addresses your question in spirit only (CTLA4 blockade independent of ido expression)..... Clin Cancer Res. 2009 Jan 1;15(1):390-9. doi: 10.1158/1078-0432.CCR-08-0783. Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Ribas A, Comin-Anduix B, Economou JS, Donahue TR, de la Rocha P, Morris LF, Jalil J, Dissette VB, Shintaku IP, Glaspy JA, Gomez-Navarro J, Cochran AJ. Division of Hematology/Oncology, Department of Medicine, University of California-Los Angeles, Los Angeles, California 90095-1782, USA. aribas@mednet.ucla.edu CTL-associated antigen 4 (CTLA4)-blocking monoclonal antibodies induce long-term regression of metastatic melanoma in some patients, but the exact mechanism is unknown. In this study, biopsies of selected accessible tumor lesions from patients treated with tremelimumab were examined to further elucidate the mechanism of its antitumor activity. EXPERIMENTAL DESIGN: Fifteen tumor biopsies from 7 patients who had been treated with tremelimumab (CP-675,206) were collected. Samples were analyzed for melanoma markers, immune cell subset markers, the presence of the T regulatory-specific transcription factor FoxP3 and the immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO). RESULTS: Clinically responding lesions had diffuse intratumoral infiltrates of CD8(+) T cells that were markedly increased in cases where comparison with a baseline biopsy was available. Nonregressing lesions had sparse, patchy CD8(+) intratumoral infiltrates. Patients with regressing lesions had an increased frequency of CD8(+) cells with or without a concomitant increase in CD4(+) cells. Two of 3 responding patients with paired samples showed a slight increase in the number of FoxP3(+) cells in the postdosing biopsies. In patients with regressing lesions who had paired samples, the intensity of IDO staining in macrophages and/or melanoma cells showed no clear pattern of change postdosing. CONCLUSIONS: Administration of tremelimumab was associated with massive intratumoral infiltrates of CD8(+) CTLs in patients with regressing tumors but had varying effects on intratumoral infiltrates of CD4(+) and FoxP3(+) cells or intratumoral expression of IDO.